期刊文献+

新剂型非典型抗精神病药富马酸喹硫平缓释片的研究进展 被引量:18

Advance in the research of quetiapine fumarate extended-release tablets,a new formulation for atypical antipsychotics
原文传递
导出
摘要 富马酸喹硫平缓释片作为非典型抗精神病药物喹硫平的缓释剂型,在国际上被广泛用于精神分裂症、双相躁狂、双相抑郁、双相维持期和广泛性焦虑障碍治疗以及抑郁症的联合治疗,每天只需用药1次,2 d内迅速达到目标剂量范围,在不降低疗效的前提下提高了患者的依从性,睡前3~4 h服用,可明显减少日间的镇静不良反应。多项临床试验证实了该剂型临床应用的安全性与有效性。 Quetiapine fumarate extended-release tablets, one of the atypical antipsychotics, are widely used in the treatment of schizophrenia, bipolar manic, bipolar depression, maintenance treatment of bipolar disorder, generalized anxiety disorder, and combined treatment of major depressive disorder in many countries and areas. Simpler titration allows patients to achieve their target effective dose more rapidly in two days. Once daily regimen improves the patients' compliance without minimizing the effect size. It is also associated with a lower intensity of sedation if taking the medication 3 -4 hours before bed. Many clinical trials have confirmed the safety and efficacy of this agent.
作者 张鸿燕
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第1期35-38,共4页 Chinese Journal of New Drugs
关键词 富马酸喹硫平 缓释 非典型抗精神病药 quetiapine fumarate extended-release atypical antipsychotics
  • 相关文献

参考文献20

  • 1LOCKLEA JC, WAHLGV1ST P, GUSTAFSSSON U,et al. Im- pact of extend-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis [J]. J Comp EffRes, 2014,3(4) :335 -344.
  • 2DATTO C, BERGGREN L, PATEL JB,et al. Self-reported seda- tion profile of immediate-release quetiapine fumaratc compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects[ J ]. Clin Ther, 2009, 31 (3) :492 - 502.
  • 3NORD M, NYBERG S, BROGREN J,et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiap- ine fumarate immediate-release and extended-release formulations in healthy subjects[ J]. lnt J Neuropsychopharmacol, 2011, 14 (10) :1357 - 1366.
  • 4JENSEN NH, RODRIGUIZ RM, CARON MG. N-Desalylquetia- pine, a potent norepinephrine reuptake inhibitor and partial 5- HT1 A Agonist, as a putative mediator of quetiapine's antidepres- sant activity [ J ]. Neuropsychopharmacology, 2008,33 ( 10 ) : 2303 - 2312.
  • 5BUI K, EARLEY W, NYBERG S. Pharmaeokinetic profile ofthe extended-release formulation of quetiapine fumarate ( quetiap- ine XR) : clinical implications[ J], Curr Med Res Opin, 2013, 29(7) :813 -825.
  • 6COLDHAM EL, ADDINGTON J, ADDINGTON D. Medication adherence of individuals with a first episode of psychosis[ J]. Ac- ta Psychiatr Scand, 2002,106 (4) :286 - 290.
  • 7舒良.精神分裂症防治指南[M]//舒良.中国精神障碍防治指南丛书.北京:北京大学医学出版社,2007:31-75.
  • 8CLAXTON AJ, CRAMER J, PIERCE C. A systematic review of the associations between dose regimens and medication compli- ance[J]. Clin Ther, 2001, 23(8):1296-1310.
  • 9KAHN RS, SCHULZ SC, PALAZOV VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-con- trolled study [ J ]. J Clin Psychiatry, 2007, 68 (6) :832 - 842.
  • 10LI HF, SHEN YF, WANG G, et al. The efficacy and safe of quetiapine fumarate extended release (XR) in the treatment of Chinese patients with an acute schizophrenic episode [ R ]. APA 2014, abstract 7280.

同被引文献136

引证文献18

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部